ETFMG Treatments, Testing and Advancements ETF

GERM is designed to give direct exposure to the biotech companies directly engaged in the testing and treatments of infectious diseases. Focused on advancements with targeted exposure to the forefront of R&D, vaccines, therapies and testing technologies.

Learn more
Image

Wedbush Announces Minority Stake in ETFMG

Wedbush Securities and ETF Managers Group (ETFMG) today announced that Wedbush has made a minority investment in ETFMG to support the continued growth of their innovative thematic ETF platform...

Read more
Image

ETFMG Extends Sponsorship of UFC Heavyweight

ETF Managers Group (ETFMG), an industry leader in bringing innovative thematic ETFs to market, has announced the extension of its headline-making partnership with powerhouse UFC heavyweight, Alexey Oleynik...

Read more
Image

Featured Funds

All Other Funds

GERM

ETFMG Adds Biotech to their Thematic ETF Lineup with GERM

SUMMIT, N.J.–(June 18, 2020) — ETFMG, a leading thematic ETF issuer, announced today the launch of its latest innovative exchange traded fund, the ETFMG Treatments, Testing and Advancements ETF (NYSE Arca: GERM). GERM seeks to answer investor demand for...

Disruptive Tech

AUM $22,343,555

AWAY

Disruptive Tech

AUM $8,345,539

VALT

Core Strategy

AUM $97,777,485

AIEQ

Core Strategy

AUM $88,516,099

BDRY

Commodity

AUM $42,552,636

ETHO

Disruptive TechCore Strategy

AUM $80,507,706

HACK

Disruptive Tech

AUM $1,431,056,989

IPAY

Disruptive Tech

AUM $728,862,709

ITEQ

Disruptive Tech

AUM $103,961,692

RISE

Commodity

AUM $5,070,778

*AUM is based on closing prices from previous market day.


At ETFMG we turn portfolio management strategies into successful ETFs and drive the ongoing operations. Sam Masucci, Founder & CEO At ETFMG we turn portfolio management strategies into successful ETFs and drive the ongoing operations. Sam Masucci, Founder & CEO Sam Masucci signs the book before ringing the Closing Bell at the NYSE on March 26, 2019.

We have all the expertise and execution capabilities necessary for success in the ETF space within our organization.

Our in-house team covers everything from product issuance to portfolio management, marketing, wholesaling, legal and compliance, providing unrivaled quality control and direct access to all disciplines.

About us

75%FIRST TO MARKET PRODUCTS

$3.6BASSETS UNDER MANAGEMENT

Learn more about our funds and their respective sectors.

Financial Professionals Login

Log in Sign up

Fund news and articles delivered to your inbox

Follow us for the latest news and updates